Colin Bond - Evotec AG Insider

EVOTF -- USA Stock  

USD 26.35  0.00  0.00%

Mr. Colin Bond is Chief Financial Officer and Member of the Management Board at Evotec AG since August 1 2010. He has almost 25 years of experience in finance positions most recently as Chief Financial Officer of Novelis Europe based in Switzerland. During his early career he worked as pharmacist auditor and management consultant for Procter Gamble Arthur Andersen and PricewaterhouseCoopers respectively. He moved into industry with Great Lakes Chemicals and then became Chief Finance Officer of Jet Aviation Group before becoming CFO EMEA for Ecolab
Age: 54  CFO Since 2010  MBA    
49 40 5 60 81 0
Bond is a qualified chartered accountant and pharmacist. He is a fellow of the Institute of Chartered Accountants in England and Wales and is a Member of the Royal Pharmaceutical Society of Great Britain. In addition, he received his MBA degree from London Business School. He is an Associate Lecturer at the Hamburg School of Business Administration.

Management Efficiency

The company has return on total asset (ROA) of 4.3 % which means that it generated profit of $4.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.24 % meaning that it generated $6.24 on every $100 dollars invested by stockholders.
The company has accumulated 212.96 M in total debt with debt to equity ratio (D/E) of 53.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.72 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Found 3 records

CFO Since

Ruth PoratAlphabet

Entity Summary

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 2178 people.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 2,178 people.

Evotec AG Leadership Team

Werner Lanthaler, President of the Management Board, CEO
Claus Braestrup, Member of the Supervisory Board
Michael Shalmi, Member of the Supervisory Board
Mario Polywka, COO and Member of Management Board
Mary Tanner, Member of the Supervisory Board
Roland Oetker, Deputy Chairman of the Supervisory Board
Andreas Pinkwart, Member of the Supervisory Board
Paul Herrling, Member of the Supervisory Board
Colin Bond, CFO and Member of Management Board
Cord Dohrmann, Chief Scientific Officer and Member of Management Board
Iris LoewFriedrich, Member of the Supervisory Board
Bernd Hirsch, Member of the Supervisory Board
Enno Spillner, CFO, Member of the Management Board
Elaine Sullivan, Member of the Supervisory Board
Wolfgang Plischke, Chairman of the Supervisory Board

Stock Performance Indicators

Did you try this?

Run CEO Directory Now


CEO Directory

Screen CEOs from public companies around the world
All  Next Launch CEO Directory

Evotec AG Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Evotec AG and BERKSHIRE HATHAWAY INC. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.